2024. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal of Cutaneous Medicine. 8, 4 (Jul. 2024), s404. DOI:https://doi.org/10.25251/skin.8.supp.404.